Spotlight On... Celgene buries the hatchet with India's Natco over generic Revlimid; Turing's crisis comms group scrambles; NICE backs Velcade, SGLT2 meds for new uses; Sanofi submits LixiLan to FDA; and more...

Celgene ($CELG) is getting in the holiday spirit, settling its Revlimid patent fight with Indian generics maker Natco. Under the settlement, Celgene will let Natco roll out copycat versions of its $5 billion bestseller starting in 2022, as long as Natco agrees to a "volume-limit license." The license restricts the amount of capsules Natco can sell, giving Celgene some breathing room before Natco's full launch in 2026. More from FiercePharma

> Turing Pharmaceuticals isn't going it alone in the PR battle touched off by pharma bad boy Martin Shkreli, its now-ex-CEO; DCI Group signed on several months ago and is helping manage crisis communications. Report

> U.K. cost-effectiveness watchdogs backed Johnson & Johnson's ($JNJ) Velcade in mantle cell lymphoma, and three SGLT2 diabetes drugs--J&J's Invokana, AstraZeneca's ($AZN) Forxiga and Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's Jardiance--as monotherapies in certain patients. Report

> Sanofi ($SNY) submitted its insulin-plus-GLP-1 diabetes drug LixiLan to the FDA, hoping for an approval next year; one half of that med, the GLP-1 Lyxumia, is awaiting an FDA nod now. Release | More

> Merck KGaA and Pfizer ($PFE) are pushing ahead with two new late-stage studies for avelumab, a PD-L1 cancer med that's playing catch-up in the immuno-oncology field. Report

And Finally... Public health officials are pushing for wider use of a Gilead Sciences ($GILD) drug to prevent HIV infection, but some AIDS groups continue to oppose it. Report

Suggested Articles

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.

AstraZeneca partners with actor and asthma sufferer Tony Hale to raise awareness about eosinophilic asthma and blood testing to diagnose it.

Pharma video ads have bounced back after initial COVID-19 shelter-in-place advice and uncertainty dampened placements.